Clinical Trials Browser

Phase 4 × Genitourinary × Clear all

NCT04108208 2026-03-16

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Phase 4 Active not recruiting

75 enrolled 9 charts

Prostatic Neoplasms

NCT07474519 2026-03-16

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

Phase 4 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06862219 2026-03-06

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase 4 Recruiting

Carcinoma, Transitional Cell

NCT03348969 2026-03-03

NICSA

Phase 4 Completed

Urinary Bladder Neoplasms

NCT05700903 2026-03-02

ARCH

Phase 4 Completed

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Phase 4 Active not recruiting

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

NCT07278362 2026-02-23

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

Phase 4 Not yet recruiting

Eunuchism, Prostatic Neoplasms

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06627530 2026-02-11

COAction

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT06733350 2026-02-09

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Phase 4 Suspended

Prostatic Neoplasms

NCT07252726 2026-02-09

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

Phase 4 Recruiting

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

NCT05348876 2026-01-30

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Phase 4 Recruiting

Prostatic Neoplasms

NCT04373564 2026-01-22

ODYSSEY

Phase 4 Recruiting

BreastEndocrineGastrointestinalGenitourinaryNET

Breast Neoplasms, Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT06660862 2026-01-08

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Phase 4 Not yet recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT05962541 2025-12-31

CUT-less

Phase 4 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT02651948 2025-12-19

Transperineal, MRI-guided, Prostate Biopsy

Phase 4 Completed

Prostatic Neoplasms

NCT05457257 2025-12-19

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4 Completed

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer

NCT05722925 2025-11-14

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT06479187 2025-11-05

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT05919329 2025-10-24

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

Phase 4 Recruiting

Castration Resistant Prostate Cancer

NCT06226129 2025-10-20

Gadopiclenol in Contrast Enhanced MRI of the Prostate

Phase 4 Recruiting

Prostatic Neoplasms

NCT07028125 2025-10-07

CANIQOL

Phase 4 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT06781879 2025-10-03

COBRA-NMIBC

Phase 4 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Recurrence

NCT06934057 2025-09-24

CABOLD

Phase 4 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06074510 2025-09-11

MIRROR

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT06604442 2025-09-11

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Phase 4 Completed

Prostatic Neoplasms

NCT04532606 2025-07-30

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

Phase 4 Recruiting

Emergence Delirium, Urinary Bladder Neoplasms, Delirium

NCT06908694 2025-07-29

GAINPCCONTROL

Phase 4 Recruiting

Prostatic Neoplasms

NCT04513522 2025-07-11

CheckMate 7C9

Phase 4 Completed

101 enrolled 12 charts

Kidney Neoplasms

NCT06903312 2025-07-03

ITALIC-RCC

Phase 4 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07001709 2025-06-03

ENABLE

Phase 4 Recruiting

Cancer Pain, Prostatic Neoplasms

NCT05805436 2025-05-30

Preop Laxatives in Robotic Urologic Surgery

Phase 4 Recruiting

GenitourinaryOther

Constipation, Kidney Neoplasms, Prostatic Neoplasms

NCT05753046 2025-04-27

TAPBlock

Phase 4 Enrolling by invitation

Prostatic Neoplasms

NCT05803941 2025-04-24

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Phase 4 Recruiting

Prostatic Neoplasms

NCT03641560 2025-04-08

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Phase 4 Completed

52 enrolled 10 charts

Metastatic Castration Resistant Prostate Cancer

NCT06875258 2025-03-13

PEHAB-II

Phase 4 Recruiting

Erectile Dysfunction Following Radical Prostatectomy

NCT04134208 2025-01-16

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Phase 4 Terminated

2 enrolled 10 charts

Prostatic Neoplasms

NCT06709196 2025-01-09

REINFORCE

Phase 4 Recruiting

Cystectomy

NCT05568537 2025-01-03

Prostate MRI and Pylarify PSMA PET/CT

Phase 4 Withdrawn

Prostatic Neoplasms

NCT02918968 2024-12-09

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

Phase 4 Completed

206 enrolled 16 charts

Prostatic Neoplasms

NCT02116582 2024-12-06

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Phase 4 Completed

215 enrolled 11 charts

Metastatic Castration-Resistant Prostate Cancer

NCT06706921 2024-11-27

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Phase 4 Recruiting

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT03035032 2024-11-26

A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients

Phase 4 Completed

107 enrolled 25 charts

Prostatic Neoplasms

NCT06390111 2024-11-22

ABLE-42

Phase 4 Withdrawn

Urinary Bladder Neoplasms

NCT05629494 2024-10-18

ADAPT-PSA

Phase 4 Recruiting

Prostatic Neoplasms, Prostatitis

NCT03821376 2024-10-10

Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)

Phase 4 Terminated

12 enrolled 6 charts

Carcinoma, Renal Cell

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4 Completed

337 enrolled 8 charts

DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT06215976 2024-08-20

The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer

Phase 4 Recruiting

Urinary Bladder Neoplasms

NCT00953277 2024-08-12

Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

Phase 4 Completed

Prostatic Neoplasms, Peripheral Nerve Injuries

NCT06548438 2024-08-12

TUR_BLUE

Phase 4 Not yet recruiting

Urinary Bladder Neoplasms